STAT-Dx Life S.L. (A QIAGEN Company), Baldiri Reixac, 4, 08028, Barcelona, Spain.
QIAGEN Inc., 19300 Germantown Road, Germantown, MD, 20874, USA.
Sci Rep. 2023 Feb 17;13(1):2833. doi: 10.1038/s41598-023-29838-9.
Recent reports from the World Health Organization regarding Influenza A cases of zoonotic origin in humans (H1v and H9N2) and publications describing emergence swine Influenza A cases in humans together with "G4" Eurasian avian-like H1N1 Influenza A virus have drawn global attention to Influenza A pandemic threat. Additionally, the current COVID-19 epidemic has stressed the importance of surveillance and preparedness to prevent potential outbreaks. One feature of the QIAstat-Dx Respiratory SARS-CoV-2 panel is the double target approach for Influenza A detection of seasonal strains affecting humans using a generic Influenza A assay plus the three specific human subtype assays. This work explores the potential use of this double target approach in the QIAstat-Dx Respiratory SARS-Co-V-2 Panel as a tool to detect zoonotic Influenza A strains. A set of recently recorded H9 and H1 spillover strains and the G4 EA Influenza A strains as example of recent zoonotic Flu A strains were subjected to detection prediction with QIAstat-Dx Respiratory SARS-CoV-2 Panel using commercial synthetic dsDNA sequences. In addition, a large set of available commercial human and non-human influenza A strains were also tested using QIAstat-Dx Respiratory SARS-CoV-2 Panel for a better understanding of detection and discrimination of Influenza A strains. Results show that QIAstat-Dx Respiratory SARS-CoV-2 Panel generic Influenza A assay detects all the recently recorded H9, H5 and H1 zoonotic spillover strains and all the G4 EA Influenza A strains. Additionally, these strains yielded negative results for the three-human seasonal IAV (H1, H3 and H1N1 pandemic) assays. Additional non-human strains corroborated those results of Flu A detection with no subtype discrimination, whereas human Influenza strains were positively discriminated. These results indicate that QIAstat-Dx Respiratory SARS-CoV-2 Panel could be a useful tool to diagnose zoonotic Influenza A strains and differentiate them from the seasonal strains commonly affecting humans.
世界卫生组织最近报告了人类中源自动物的流感 A 病例(H1v 和 H9N2),以及描述在人类中出现的新型猪流感 A 病例的出版物,同时还出现了“G4”欧亚类禽流感 H1N1 流感 A 病毒,这引起了全球对流感 A 大流行威胁的关注。此外,当前的 COVID-19 疫情强调了监测和准备工作的重要性,以预防潜在的疫情爆发。QIAs tat-Dx 呼吸道 SARS-CoV-2 检测试剂盒的一个特点是,使用通用流感 A 检测方法和三种特定的人类亚型检测方法,对影响人类的季节性流感 A 菌株进行双重检测,以检测流感 A。本研究探索了在 QIAstat-Dx 呼吸道 SARS-CoV-2 检测试剂盒中使用这种双重检测方法的潜力,作为检测人畜共患流感 A 菌株的工具。最近记录的一组 H9 和 H1 溢出菌株以及 G4 EA 流感 A 菌株作为最近人畜共患流感 A 菌株的例子,使用商业合成 dsDNA 序列进行 QIAstat-Dx 呼吸道 SARS-CoV-2 检测试剂盒的检测预测。此外,还使用 QIAstat-Dx 呼吸道 SARS-CoV-2 检测试剂盒对大量可用的商业人类和非人类流感 A 菌株进行了测试,以更好地了解流感 A 菌株的检测和区分。结果表明,QIAs tat-Dx 呼吸道 SARS-CoV-2 检测试剂盒的通用流感 A 检测方法可检测到所有最近记录的 H9、H5 和 H1 人畜共患溢出菌株以及所有 G4 EA 流感 A 菌株。此外,这些菌株在三种人类季节性 IAV(H1、H3 和 H1N1 大流行)检测方法中均呈阴性结果。其他非人类菌株证实了这些流感 A 检测结果,没有亚型区分,而人类流感菌株则得到了阳性区分。这些结果表明,QIAs tat-Dx 呼吸道 SARS-CoV-2 检测试剂盒可能是诊断人畜共患流感 A 菌株并将其与通常影响人类的季节性菌株区分开来的有用工具。